-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Altamira Therapeutics (NASDAQ:CYTO) Shares Down 2.9%
Altamira Therapeutics (NASDAQ:CYTO) Shares Down 2.9%
Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Rating) fell 2.9% during trading on Friday . The company traded as low as $0.35 and last traded at $0.38. 125,689 shares traded hands during trading, a decline of 87% from the average session volume of 980,736 shares. The stock had previously closed at $0.39.
Altamira Therapeutics Price Performance
The firm's fifty day moving average price is $0.43 and its 200 day moving average price is $0.68.
Get Altamira Therapeutics alerts:Hedge Funds Weigh In On Altamira Therapeutics
A hedge fund recently raised its stake in Altamira Therapeutics stock. BlackRock Inc. grew its stake in Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Rating) by 84.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,603 shares of the company's stock after acquiring an additional 28,151 shares during the quarter. BlackRock Inc. owned about 0.41% of Altamira Therapeutics worth $67,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.75% of the company's stock.
Altamira Therapeutics Company Profile
(Get Rating)Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.
Recommended Stories
- Get a free copy of the StockNews.com research report on Altamira Therapeutics (CYTO)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Rating) fell 2.9% during trading on Friday . The company traded as low as $0.35 and last traded at $0.38. 125,689 shares traded hands during trading, a decline of 87% from the average session volume of 980,736 shares. The stock had previously closed at $0.39.
阿尔塔米拉治疗有限公司(纳斯达克代码：Cyto-Get评级)在周五的交易中下跌2.9%。该公司股价低至0.35美元，最新报0.38美元。当日成交量为125,689股，较当日平均成交量980,736股下降87%。该股此前收盘价为0.39美元。
Altamira Therapeutics Price Performance
阿尔塔米拉治疗药物性价比
The firm's fifty day moving average price is $0.43 and its 200 day moving average price is $0.68.
该公司的50日移动均线价格为0.43美元，200日移动均线价格为0.68美元。
Hedge Funds Weigh In On Altamira Therapeutics
对冲基金入股阿尔塔米拉治疗公司
A hedge fund recently raised its stake in Altamira Therapeutics stock. BlackRock Inc. grew its stake in Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Rating) by 84.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,603 shares of the company's stock after acquiring an additional 28,151 shares during the quarter. BlackRock Inc. owned about 0.41% of Altamira Therapeutics worth $67,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.75% of the company's stock.
一家对冲基金最近增持了阿尔塔米拉治疗公司的股票。根据贝莱德公司提交给美国证券交易委员会的最新的13F文件，今年第一季度，该公司在阿尔塔米拉治疗有限公司(纳斯达克：Cyto-Get Rating)的持股增加了84.2%。该公司在本季度增持了28,151股后，持有61,603股该公司股票。截至最近一个季度末，贝莱德拥有阿尔塔米拉治疗公司约0.41%的股份，价值67,000美元。机构投资者和对冲基金持有该公司9.75%的股票。
Altamira Therapeutics Company Profile
阿尔塔米拉治疗公司简介
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.
阿尔塔米拉治疗有限公司致力于开发解决各种未得到满足的医疗需求的疗法。它的商业产品包括Bentrio，一种用于个人防护空气传播病毒和过敏原的无药物鼻喷雾剂。该公司还参与了用于肝外治疗靶点的RNA疗法的开发，包括处于寡核苷酸和信使核糖核酸输送的临床前阶段的寡聚和信号灯平台；用于鼻腔治疗眩晕的AM-125处于第二阶段临床试验；用于治疗急性内耳耳鸣的Keyzilen处于第三阶段临床试验；以及用于治疗急性内耳听力损失的Sonsuvi处于临床开发第三阶段。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Altamira Therapeutics (CYTO)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- 免费获取StockNews.com关于阿尔塔米拉治疗公司(Cyto)的研究报告
- 股市：红海中的三座强国
- 第四季度值得考虑的3家银行
- 有什么办法可以治愈Teladoc股票的问题吗？
- 没有人告诉这三只股票这是下跌的一周
- MarketBeat：回顾一周9/12-9/16
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《阿尔塔米拉治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对AlTamira治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧